Liu Jiaqi, Hu Gejile, Du Hua, Shi Yingxu
Department of Laboratory Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010010, P.R. China.
Department of Pathology, College of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010010, P.R. China.
Oncol Rep. 2025 Aug;54(2). doi: 10.3892/or.2025.8924. Epub 2025 Jun 6.
In recent years, the role of microRNAs (miRNAs) in disease has attracted considerable interest, underscoring their potential utility as diagnostic biomarkers. miR‑100, belonging to the miR‑99 family, is integral to the pathophysiological processes underlying numerous diseases. miR‑100 has been found to influence the pathogenesis of a variety of noncancerous diseases. As for cancer, this factor plays a significant role in various tumors throughout diverse systems, influencing essential processes including cell proliferation, invasion, migration and apoptosis of cancerous cells. This review examines the existing literature on miR‑100 in the context of non‑cancerous diseases and cancer, investigates its mechanisms of action across different diseases and considers its potential role as a diagnostic biomarker as well as its involvement in cancer drug resistance.
近年来,微小RNA(miRNA)在疾病中的作用引起了广泛关注,凸显了其作为诊断生物标志物的潜在效用。miR-100属于miR-99家族,是众多疾病病理生理过程的重要组成部分。已发现miR-100影响多种非癌性疾病的发病机制。至于癌症,该因子在不同系统的各种肿瘤中发挥重要作用,影响癌细胞的细胞增殖、侵袭、迁移和凋亡等关键过程。本综述在非癌性疾病和癌症背景下审视了关于miR-100的现有文献,研究其在不同疾病中的作用机制,并探讨其作为诊断生物标志物的潜在作用以及其与癌症耐药性的关系。
Front Immunol. 2025-6-3
Mol Biol Rep. 2025-6-18
Zhongguo Fei Ai Za Zhi. 2025-5-20
ACS Biomater Sci Eng. 2024-12-9